Sarah Cannon Research Institute

Extended dosing of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been approved by the MHRA for use in the ongoing Phase 1 clinical trial Oxford, UK – 20th February 2025 Press Release: First patient treated with new exetended dosing of OVM-200 Oxford Vacmedix (OVM) announced today the first patient being treated with new extended dosing of OVM-200, at the prestigious Sarah Cannon Research Institute in London. The extended dosing protocol was first suggested by the clinical investiga...